4 November 2016

Soundbite Medical Solutions has announced a third investment in its seed funding round, this time for the sum of $5M.

The funding, co-managed by Canadian investors Accel-Rx Health Sciences Accelerator, BDC Capital, and the Bertrand group, brings the total funds raised to $14M in roughly a year.

These amounts will enable Soundbite to speed up the clinical validation and marketing of its technology. Human clinical trials are planned to start by the end of 2016.

In addition, the company is preparing to send a submission for CE marking during the third quarter of 2017, as well as a submission to the Food and Drug Administration (FDA) in 2018 as part of the peripheral chronic total occlusion (CTO) program.

Soundbite’s technological platform, which was created in the Université de Sherbrooke’s labs, transmits high-energy shock waves through guide wires to open blocked blood vessels.

Source: Soundbite Medical Solutions

——————————————–

RELATED ARTICLES

» Soundbite Medical Solutions launches R&D activities in Sherbrooke